C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 3, 2008, Pages 220-226

  Testa, R ^a   Bonfigli, A R ^a   Sirolla, C ^a   Marra, M ^a   Boemi, M ^a   Mari, D ^b   Sacchi, E ^c   Dolci, A ^d   Catalano, A ^a   Procopio, A ^a   Ceriello, A ^e  

^a INRCA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

C reactive protein; Fibrinolysis; PAI 1 genotype; Plasminogen activator inhibitor type 1; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PROMOTER REGION; REGRESSION ANALYSIS;

C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); REGRESSION ANALYSIS;

EID: 40649125810     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.10.001     Document Type: Article

References (34)

1. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
2. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
3. Torzewski M., Rist C., Mortensen R.F., Zwaka T.P., Bienek M., Waltenberger J., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20 (2000) 2094-2099
4. Devaraj S., Kumaresan P.R., and Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 36 (2004) 405-410
5. Verma S., Kuliszewski M.A., Li S.H., Szmitko P.E., Zucco L., Wang C.H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
6. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 (2002) 913-919
7. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., and Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82 (1993) 513-520
8. Fichtlscherer S., Rosenberger G., Walter D.H., Breuer S., Dimmeler S., and Zeiher A.M. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102 (2000) 1000-1006
9. Cleland S.J., Sattar N., Petrie J.R., Forouhi N.G., Elliott H.L., and Connell J.M. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 98 (2000) 531-535
10. Tomai F., Crea F., Gaspardone A., Versaci F., Ghini A.S., Chiariello L., et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 104 (2001) 1471-1476
11. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 (2003) 398-404
12. Nakakuki T., Ito M., Iwasaki H., Kureishi Y., Okamoto R., Moriki N., et al. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 in endothelial cells. Arterioscler Thromb Vasc Biol 25 (2005) 2088-2093
13. Levin E.G. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood 67 (1986) 1309-1313
14. Sprengers E.D., and Kluft C. Plasminogen activator inhibitors. Blood 69 (1987) 381-387
15. Hamsten A., Wiman B., de Faire U., and Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of myocardial infarction. N Engl J Med 313 (1985) 1557-1563
16. Dawson S., and Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 95 (1992) 105-117
17. Schneider D.J., Nordt T.K., and Sobel B.E. Attenuated fibrinolysis and accelerated atherogenesis in type ll diabetic patients. Diabetes 42 (1993) 1-7
18. Burzotta F., Di Castelnuovo A., Amore C., D'Orazio A., Di Bitondo R., Donati M.B., et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 79 (1998) 354-358
19. Humphries S.E., Panahloo A., Montgomery H.E., Green F., and Yudkin J. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 78 (1997) 457-461
20. Sartori M.T., Wiman B., Vettore S., Dazzi F., Girolami A., and Patrassi G.M. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 80 (1998) 956-960
21. Nordt T.K., Lohrmann J., and Bode C. Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis. Thromb Res 103 (2001) S1-S5 10.1016/S0049-3848(01)00292-4
22. Dawson S., Wiman B., Hamsten A., Greenm F., Humphries S., and Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1993) 10739-10745
23. Mannucci P.M., Mari D., Merati G., Peyvandi F., Tagliabue L., Sacchi E., et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol 17 (1997) 755-759
24. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
25. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
26. Sjoholm A., and Nystrom T. Endothelial inflammation in insulin resistance. Lancet 365 (2005) 610-612 10.1016/S0140-6736(05)17912-4
27. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
28. Aso Y., Wakabayashi S., Yamamoto R., Matsutomo R., Takebayashi K., and Inukai T. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes. Diabetes Care 28 (2005) 2216
29. Hoekstra T., Geleijnse J.M., Schouten E.G., Kok F.J., and Kluft C. Relationship of C-reactive protein with components of the metabolic syndrome in normal-weight and overweight elderly. Nutr Metab Cardiovasc Dis 15 (2005) 270-278 10.1016/j.numecd.2005.01.004
30. Bonfigli A.R., Marra M., Sirolla C., Boemi M., Mari D., Sacchi E., et al. Interleukin-6 is a determinant of PAI-1 levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene. Thromb Haemost 95 (2006) 587-588
31. Pickup J.C., Mattock M.B., Chusney G.D., and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (1997) 1286-1292
32. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214 10.1016/S0021-9150(99)00463-3
33. Hoekstra T., Geleijnse J.M., Schouten E.G., and Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 91 (2004) 861-872
34. Mansfield M.W., Stickland M.H., and Grant P.J. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 74 (1995) 1032-1034